Vactosertib

Oral, potent and selective TGFBRI (ALK5) inhibitor

Clinical Trial Information

Clinical Trial Information
Type Indication Combination Agent Country Link
Solid Tumor Chemotherapy
Combination
Gastric Cancer Paclitaxel KOR
Gastric Cancer Paclitaxel, Ramucirumab KOR
Pancreatic Cancer FOLFOX KOR
Pancreatic Cancer 5FU/LV/Onivyde KOR
Targeted therapy
combination
Desmoid sarcoma Imatinib KOR
Immunotherapy
Combination
Colorectal & Gastric Cancer Pembrolizumab KOR
NSCLC Pembrolizumab KOR
NSCLC Durvalumab KOR
Bladder Cancer Durvalumab USA
Hema Immunomodulatory agent
combination
Multiple myeloma Pomalidomide USA

Presentations & Publications

Presentations & Publications
Name Title Date PDF
SITC 2021 Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the survival of MSS mCRC patients treated vactosertib in combination with pembrolizumab Nov 2021
SITC 2021 Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertibin combination with pembrolizumab Nov 2021
ASCO 2021 Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer June 2021
ASCO 2021 Phase 1b trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach by Targeting TGF-β Signaling Pathway June 2021
AACR 2021 BAG2 Promotes Tumorigenesis and Metastasis by Regulating the Cathepsin B Cleavage in Triple Negative Breast Cancer Cells Apr 2021
AACR 2021 DRAK1 suppresses inflammation induced cervical cancer progression by targeting TRAF6 protein Apr 2021
AACR 2021 Beneficial effect of vactosertib combined with nal IRI5 FULV in pancreatic cancer treatment Apr 2021
AACR 2021 Genomic and transcriptomic analyses of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature Apr 2021
SITC 2020 Vactosertib and Durvalumab as Second or Later Line Treatment for PD-L1 Positive Non-small Cell Lung Cancer: Interim Result Nov 2021
ASCO 2020 A Phase 1 study of TGF-β inhibitor, Vactosertib, in combination with Imatinib in patients with advanced desmoid tumor (aggressive fibromatosis) May 2020
SITC 2019 Safety and Preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase
inhibitor, in combination with Durvalumab in advanced Non-small cell lung cancer
patients with low PD-L1 expression
Nov 2019
SITC 2019 Safety and preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase
inhibitor, in combination with Pembrolizumab in patients with metastatic colorectal
or gastric cancer
Nov 2019
Innovation in AYA cancer TGF-β as a promising therapeutic target for treating Osteosarcoma Nov 2019
ASCO 2018 TGF-β Responsive signature is associated with anti-tumor effect of Vactosertib,
a potent oral TGF-β receptor type1(TGFBRI) inhibitor in patients
with advanced solid tumors
Jun 2018